On April 28, 2024，Juncell Therapeutics today announced that National Medical Products Administration (NMPA) has allowed an Investigational New Drug Application (IND) to proceed for its first genetically modified TIL therapy, GC203 , for the treatment of advanced malignant solid tumors.

GC203 is a novel non-viral vector gene-modified TIL therapy developed leveraging Juncell Therapeutics' proprietary DeepTIL™ cell expansion platform and NovaGMP™ gene modification platform. DeepTIL™ enables TILs to be potent enough that no IL-2 combination will be required after infusion, and the intensity of lymphodepletion could be lower. NovaGMP™ modifies T cells with a high efficiency comparable with the Lentiviral vector in an economic way. GC203 is engineered with self-associating membrane-bound interleukin-7, which can maintain the stemness of memory T cells, activate internal immune cells and avoid systemic toxicities.

A poster highlighting preclinical activity and characterization of GC203 will be presented at the upcoming American Association for Cancer Research (AACR) 2024 Annual Meeting.

Juncell Contact: